Project Grant HT94252410417
Award Date
9/30/24
Completion Date
9/29/27
Dollars Obligated
$705K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Evanston, IL 60208, USA
Similar Awards
This $762,992 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by the University of Texas MD Anderson Cancer Center to map and predict therapy resistance in small cell lung cancer (SCLC) using liquid biopsies. The 3-year award, effective July 1, 2024, will enable MD Anderson to conduct personalized analyses to better understand how SCLC tumors evolve and become resistant to treatment. This work aims to...
This federal Project Grant award of $188,403 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research at the University of California, Los Angeles (UCLA) to develop new cell-mediated immunotherapeutic strategies for small-cell lung cancer. The award, effective from January 1, 2025 to December 31, 2025, will fund advanced biomedical research initiatives at UCLA targeting innovative treatments for this form of lung cancer. The Military...
The Defense Health Agency awarded a $828,591 Project Grant under CFDA 12.420, the Military Medical Research and Development program, to Duke University. The grant supports research titled "Targeting the Tumor Microenvironment to Enhance Immunotherapy for SCLC", with a performance period from May 1, 2025 to April 30, 2027. This research aims to transform healthcare for military service members, veterans, and the public by advancing innovative biomedical investigations focused on...
The Albert Einstein College of Medicine has been awarded a $882,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to develop a novel targeted drug therapy to treat small cell lung cancer (SCLC). The award will support research activities from June 1, 2024 through May 31, 2027. As a highly experienced recipient of federal research grants and contracts, the college has a track record of conducting biomedical research and...
This $819,841 federal Project Grant awarded by the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), supports Duke University's research to pharmacologically activate a newly discovered KEAP1-ATF4-CHOP axis in order to select against targeted therapy resistance in non-small cell lung cancer (NSCLC). The research project aims to develop new treatments that can overcome resistance to existing targeted therapies for NSCLC. Duke University, through its...
The Defense Health Agency awarded a $168,200 Project Grant to Health Research, Inc. Roswell Park Division under the Military Medical Research and Development program (CFDA 12.420) to investigate alternative polyadenylation as a mediator of therapeutic resistance in lung cancer. The two-year award beginning July 1, 2021 will support research into innovative medical solutions for lung cancer treatment through the study of alternative polyadenylation, a novel area of investigation that could help...
The Defense Health Agency awarded a $923,805 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Sloan-Kettering Institute for Cancer Research in New York. The grant supports a 3-year research project titled "Systematic Functional Dissection of Cancer Cell States in Lung Tumors" starting September 1, 2025. The grant aims to conduct advanced biomedical research to transform healthcare for military service members, veterans, and the broader...
The U.S. Defense Health Agency awarded a $1,056,000.00 Project Grant to the Beckman Research Institute of the City of Hope, a nonprofit organization, to conduct research on PP2A as a promising biomarker and therapeutic target in small cell lung cancer. The grant period runs from September 1, 2023 to August 31, 2026 under the Military Medical Research and Development program (CFDA 12.420). The Beckman Research Institute, which has prior experience collaborating on federal health research...
The federal Project Grant award of $924,001.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research by the Sloan-Kettering Institute for Cancer Research to investigate the cellular and molecular origins of non-small cell lung cancer (NSCLC) brain metastasis. The research aims to enhance understanding of the mechanisms driving NSCLC brain metastasis, with the goal of developing innovative therapeutic...
The Defense Health Agency awarded a $924,000 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to the Sloan-Kettering Institute for Cancer Research in New York, NY. The grant, titled "Therapeutic Strategies for Targeting Diverse KRAS Mutations in Lung Cancer," will fund advanced cancer research focused on developing innovative treatments for lung cancer. The research aims to investigate therapeutic approaches for targeting diverse KRAS mutations, a...